Wedbush Keeps a Buy Rating on miRagen Therapeutics Inc

By Ryan Adsit

Wedbush analyst Liana Moussatos reiterated a Buy rating on miRagen Therapeutics Inc (NASDAQ: MGEN) today and set a price target of $19. The company’s shares opened today at $7.98.

According to TipRanks.com, Moussatos is a 4-star analyst with an average return of 10.9% and a 43.8% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as KalVista Pharmaceuticals Inc, Allena Pharmaceuticals Inc, and Catabasis Pharmaceuticals.

miRagen Therapeutics Inc has an analyst consensus of Strong Buy, with a price target consensus of $24.

The company has a one-year high of $18 and a one-year low of $4.65. Currently, miRagen Therapeutics Inc has an average volume of 85.27K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Signal Genetics, Inc. is a commercial stage, molecular diagnostic company. It provides innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer. The company was founded in January 2010 and is headquartered in Carlsbad, CA.